<DOC>
	<DOCNO>NCT01981720</DOCNO>
	<brief_summary>To evaluate ongoing safety , tolerability , efficacy parameter PRX-102 adult Fabry patient successfully complete treatment PRX-102 study PB-102-F01 PB-102-F02 . Patients enrol receive dose PRX-102 ( 0.2 mg/kg , 1.0 mg/kg , 2.0 mg/kg ) , intravenous infusion every 2 week 24 Months .</brief_summary>
	<brief_title>Extension Study PRX-102 24 Months</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Completion study PB102F02 The patient sign inform consent Female patient male patient whose copartner childbearing potential agree use medically acceptable method contraception , include rhythm method . Acceptable method contraception include hormonal product , intrauterine device , male female condom . Contraception use 1 month treatment termination . Pregnant nursing Presence medical , emotional , behavioral psychological condition , judgment Investigator and/or Medical Director , would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>